Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (51-60 of 166) with videos related to

Pageof 17
Sort By:
Molecular Cancer Therapeutics|March 6, 2012
Inhibition of OCTN2-mediated transport of carnitine by etoposideChaoxin Hu, Cynthia S Lancaster, Zhili Zuo, et al.
Clinical Pharmacology and Therapeutics|October 31, 2003
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approachesAlbert J Ten Tije, Walter J Loos, Jaap Verweij, et al.
Expert Review of Clinical Pharmacology|December 19, 2025
Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitorsJack C Stromatt, Anika T Chowdhury, Kevin M Huang, et al.
Cancer Biology & Therapy|February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsJing Li, George Cusatis, Julie Brahmer, et al.
Neuro-Oncology|April 16, 2005
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich, Sharyn D Baker, Stuart A Grossman, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 29, 2005
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studiesMichelle A Rudek, Ming Zhao, Ping He, et al.
Clinical and Translational Science|June 22, 2023
DNA methyltransferase inhibitor exposure-response: Challenges and opportunitiesAmanda B Kagan, Dominique A Garrison, Nicole M Anders, et al.
Oncology (Williston Park, N.Y.)|October 23, 2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary reportRamaswamy Govindan, William Read, Joan Faust, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
Pageof 17

Showing results (51-60 of 166) with videos related to

Sort By:
Pageof 17
Molecular Cancer Therapeutics|March 6, 2012
Inhibition of OCTN2-mediated transport of carnitine by etoposideChaoxin Hu, Cynthia S Lancaster, Zhili Zuo, et al.
Clinical Pharmacology and Therapeutics|October 31, 2003
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approachesAlbert J Ten Tije, Walter J Loos, Jaap Verweij, et al.
Expert Review of Clinical Pharmacology|December 19, 2025
Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitorsJack C Stromatt, Anika T Chowdhury, Kevin M Huang, et al.
Cancer Biology & Therapy|February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsJing Li, George Cusatis, Julie Brahmer, et al.
Neuro-Oncology|April 16, 2005
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich, Sharyn D Baker, Stuart A Grossman, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 29, 2005
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studiesMichelle A Rudek, Ming Zhao, Ping He, et al.
Clinical and Translational Science|June 22, 2023
DNA methyltransferase inhibitor exposure-response: Challenges and opportunitiesAmanda B Kagan, Dominique A Garrison, Nicole M Anders, et al.
Oncology (Williston Park, N.Y.)|October 23, 2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary reportRamaswamy Govindan, William Read, Joan Faust, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
Pageof 17